2023
Dose prescription and reporting in stereotactic body radiotherapy: A multi-institutional study
Das I, Yadav P, Andersen A, Chen Z, Huang L, Langer M, Lee C, Li L, Popple R, Rice R, Schiff P, Zhu T, Abazeed M. Dose prescription and reporting in stereotactic body radiotherapy: A multi-institutional study. Radiotherapy And Oncology 2023, 182: 109571. PMID: 36822361, PMCID: PMC10121952, DOI: 10.1016/j.radonc.2023.109571.Peer-Reviewed Original ResearchConceptsDose prescriptionTreatment-related toxicityClinical outcome comparisonStereotactic body radiotherapyMulti-institutional studyTreatment guidelinesTreatment disparitiesBody radiotherapyPTV volumeClinical trialsTreatment protocolOutcome comparisonsTreatment efficacyAbstractTextHypofractionated treatmentDosimetric parametersDose parametersDosimetric variabilityDosimetric variationsStandardized reportingLack of standardization
2017
Incorporating patient-specific CT-based ophthalmic anatomy in modeling iodine-125 eye plaque brachytherapy dose distributions
Tien CJ, Astrahan MA, Kim JM, Materin M, Chen Z, Nath R, Liu W. Incorporating patient-specific CT-based ophthalmic anatomy in modeling iodine-125 eye plaque brachytherapy dose distributions. Brachytherapy 2017, 16: 1057-1064. PMID: 28778599, DOI: 10.1016/j.brachy.2017.06.014.Peer-Reviewed Original ResearchConceptsEye modelDisc distanceDose differenceTumor apexPrescription doseOcular parametersPlaque SimulatorOcular structuresSubstantial dose differencesTarget volumePlaque positionDosimetric parametersPatientsClinical planningDosimetric impactSignificant differencesBrachytherapy planningSeed strengthPlaquesBrachytherapy dose distributionsDose distributionPatient-specific modelsDifferencesTumorsRetina
1998
Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants
Nath R, Roberts K, Ng M, Peschel R, Chen Z. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants. Medical Physics 1998, 25: 2293-2307. PMID: 9874821, DOI: 10.1118/1.598440.Peer-Reviewed Original ResearchConceptsSurvival rateProstate cancerInterstitial implantsLocal recurrence-free survival rateRecurrence-free survival ratesLocal control rateLocal tumor controlExcellent clinical resultsProstate cancer patientsUnfavorable groupClinical efficacyCancer patientsControl rateTumor controlClinical resultsFavorable groupDose coveragePatientsDosimetric parametersDosimetry parametersIsodose surfaceSignificant differencesVirginia studyUnfavorable parametersCancer